Stephen L. Silvestro - 23 Dec 2024 Form 4 Insider Report for OptimizeRx Corp (OPRX)

Role
Chief Commercial Officer
Signature
/s/ Marion Odence-Ford, by Power of Attorney
Issuer symbol
OPRX
Transactions as of
23 Dec 2024
Transactions value $
$0
Form type
4
Filing time
27 Dec 2024, 15:18:54 UTC
Previous filing
20 Dec 2024
Next filing
20 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPRX Common Stock Award $0 +41,408 +51.2% $0.000000 122,256 23 Dec 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OPRX Stock Option Award $0 +77,742 $0.000000 77,742 23 Dec 2024 Common Stock 77,742 $4.83 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on December 23, 2025, which is the first anniversary of the date of grant.
F2 The stock option vests in three equal annual installments beginning December 23, 2025, the first anniversary of the grant date.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.